Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
15 studies found for:    Lupus AND Los Angeles | Open Studies
Show Display Options
Download search resultsDownload the search results for:
Lupus AND Los Angeles | Open Studies (15 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Recruiting A Complex Contraception Registry
Conditions: Diabetes;   Cardiovascular Disease;   Epilepsy;   Migraine;   Neurological Disorders;   Cancer;   Bariatric Surgery;   Solid Organ Transplant;   Systemic Lupus Erythematous;   Rheumatologic Conditions;   Venous Thrombosis Embolism
Intervention:
2 Recruiting A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
Condition: Systemic Lupus Erythematosus
Interventions: Drug: CC-220;   Drug: Placebo
3 Recruiting Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
4 Recruiting Nelfinavir in Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Nelfinavir
5 Recruiting Functional MRI in Lupus Nephritis
Condition: Lupus Nephritis
Intervention:
6 Recruiting A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
Conditions: Lupus Erythematosus, Cutaneous;   Lupus Erythematosus, Systemic;   Lupus Erythematosus, Discoid;   Healthy
Interventions: Procedure: Skin biopsy;   Procedure: Blood collection;   Procedure: Urine collection
7 Recruiting Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
Condition: Systemic Lupus Erythematosus
Interventions: Biological: BENLYSTA;   Other: SLE treatment
8 Recruiting Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
Condition: Lupus
Interventions: Drug: BMS-931699;   Drug: Placebo matching BMS-931699
9 Recruiting Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
10 Recruiting Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: Atacicept 75 milligram (mg);   Drug: Atacicept 150 mg;   Drug: Placebo
11 Recruiting Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)
Condition: Lupus Erythematosus, Systemic
Interventions: Drug: Mycophenolate Mofetil;   Drug: Hydroxychloroquine or Chloroquine;   Drug: Prednisone
12 Recruiting BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: BIIB023;   Biological: Placebo;   Drug: Mycophenolate Mofetil;   Drug: Oral corticosteroid regimen
13 Recruiting Belimumab Assessment of Safety in SLE
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Other: Standard therapy
14 Recruiting Be the Bridge Between Researchers and a Cure (GVHD, ALS, Hepatitis B, Alzheimer's Disease, Leukemia, and More)
Condition: All Diagnosed Health Conditions
Intervention:
15 Recruiting Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Interventions: Drug: tofacitinib;   Biological: adalimumab;   Biological: etanercept

Indicates status has not been verified in more than two years